Funded Tech Companies
DEM BioPharma
DEM BioPharma, based in Cambridge, raised money through Pfizer Venture Investments, Astellas Venture Capital and Alexandria Venture Investments.
Company Overview
Company Name
DEM BioPharma
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
lexandria LaunchLabs, One Kendall Square, Building 200, 001
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
DEM Bio is pioneering the next generation of immunotherapeutics designed to unleash macrophages and other myeloid effector cells to eliminate tumors by targeting novel 'don't eat me' (DEM) and 'eat me' (EM) signals on cancer cells and macrophages. Our proprietary CHoMP� platform (Co-culture with Human Myeloid Phagocytes) will be used to identify unexplored DEM and EM signals in a systematic and unbiased manner via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells. DEM Bio was co-founded by the Longwood Fund and distinguished scientists Drs. Jonathan Weissman, Kipp Weiskopf, and Michael Bassik.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
6/23/2022
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chairman
Jan Skvarka
Chief Executive Officer
David Donabedian
Chief Operating Officer
John McCabe
Co-Founder
John Pribis
Co-Founder
Annie Vemu
Company Investors
- Pfizer Venture Investments
- Astellas Venture Capital
- Alexandria Venture Investments
- Insight Venture Partners
- Longwood Fund
- Alta Partners
- UTokyo Innovation Platform
- Emerson Collective
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This tech company profile is powered by VentureDeal.com, a leading supplier of venture capital funding data.
Additional Resources for Entrepreneurs